German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments

Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.

Germany Clinic — Clinical cancer registries could help companies gather better comparative data • Source: Shutterstock

With some improvements, clinical cancer registries that exist in every federal state in Germany could be an important new source of comparative data to support submissions for new oncology products undergoing Amnog benefit assessments, according to Volker Vervölgyi, division head of the drug assessment department at IQWiG, Germany’s health technology appraisal institute.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

25 Apr 2025

• By Eliza Slawther

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.

EMA’s Role In Regulatory Reliance For Post-Approval Changes

25 Apr 2025

• By Vibha Sharma

The European Medicines Agency’s assessments of applications for variations play a key role in supporting international regulatory reliance mechanisms. Companies can aid this by ensuring the scope of their post-approval changes is clear, and notifying the EMA when sharing reports with non-EU regulators.

Semaglutide For MASH Among Raft Of New EU Filings

24 Apr 2025

• By Neena Brizmohun

Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.

SpringWorks To Make Its Case For Nirogacestat At High-Stakes EMA Meeting

24 Apr 2025

• By Francesca Bruce

Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.

Pink Sheet Podcast: More US FDA Departures, Makary On Combined AE Database, ‘Conditional’ Approval

25 Apr 2025

• By Derrick Gingery, Sarah Karlin-Smith, and Sue Sutter

Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.